Freenome, Inc. filed an Amendment No. 1 to its Current Report on Form 8-K to include unaudited condensed consolidated financial statements and Management’s Discussion and Analysis for the three and six months ended June 30, 2026, along with pro forma combined financial information following the completion of a business combination with Perceptive Capital Solutions Corp. on July 20, 2026. The transaction resulted in net proceeds of approximately $295.5 million, including $240.0 million from a PIPE financing. For the six months ended June 30, 2026, Freenome reported total revenue of $6.5 million and a net loss of $132.6 million. The company also disclosed that its SimpleScreen CRC test received FDA approval in July 2026, triggering a $100.0 million milestone payment from Exact Sciences under an exclusive license agreement. Freenome operates as an early cancer detection company developing blood-based screening tests leveraging AI/ML.
